EP0938326A4 - Synthetic phosphopeptides for treating bone diseases - Google Patents

Synthetic phosphopeptides for treating bone diseases

Info

Publication number
EP0938326A4
EP0938326A4 EP97932409A EP97932409A EP0938326A4 EP 0938326 A4 EP0938326 A4 EP 0938326A4 EP 97932409 A EP97932409 A EP 97932409A EP 97932409 A EP97932409 A EP 97932409A EP 0938326 A4 EP0938326 A4 EP 0938326A4
Authority
EP
European Patent Office
Prior art keywords
bone diseases
treating bone
phosphopeptides
synthetic phosphopeptides
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP97932409A
Other languages
German (de)
French (fr)
Other versions
EP0938326B1 (en
EP0938326A1 (en
Inventor
Yoshinari Kumagai
Akira Otaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Big Bear Bio Inc
Original Assignee
Big Bear Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Big Bear Bio Inc filed Critical Big Bear Bio Inc
Priority to DK97932409T priority Critical patent/DK0938326T3/en
Publication of EP0938326A1 publication Critical patent/EP0938326A1/en
Publication of EP0938326A4 publication Critical patent/EP0938326A4/en
Application granted granted Critical
Publication of EP0938326B1 publication Critical patent/EP0938326B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/16Phosphorus containing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Phosphopeptides which significantly reduce bone loss or weakening are provided by the invention. Also provided is a method for treating or preventing any condition associated with bone loss or weakening by administering the phosphopeptides by oral or injectable means.
EP97932409A 1996-07-03 1997-06-30 Synthetic phosphopeptides for treating bone diseases Expired - Lifetime EP0938326B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK97932409T DK0938326T3 (en) 1996-07-03 1997-06-30 Synthetic phosphopeptides for the treatment of bone diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/675,031 US5837674A (en) 1996-07-03 1996-07-03 Phosphopeptides and methods of treating bone diseases
US675031 1996-07-03
PCT/US1997/011426 WO1998000156A1 (en) 1996-07-03 1997-06-30 Synthetic phosphopeptides for treating bone diseases

Publications (3)

Publication Number Publication Date
EP0938326A1 EP0938326A1 (en) 1999-09-01
EP0938326A4 true EP0938326A4 (en) 2002-07-03
EP0938326B1 EP0938326B1 (en) 2004-09-15

Family

ID=24708791

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97932409A Expired - Lifetime EP0938326B1 (en) 1996-07-03 1997-06-30 Synthetic phosphopeptides for treating bone diseases

Country Status (11)

Country Link
US (2) US5837674A (en)
EP (1) EP0938326B1 (en)
JP (2) JP2001503452A (en)
AT (1) ATE275961T1 (en)
AU (1) AU727675B2 (en)
CA (1) CA2258661C (en)
DE (1) DE69730725T2 (en)
DK (1) DK0938326T3 (en)
ES (1) ES2224260T3 (en)
PT (1) PT938326E (en)
WO (1) WO1998000156A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837674A (en) * 1996-07-03 1998-11-17 Big Bear Bio, Inc. Phosphopeptides and methods of treating bone diseases
US20030118572A1 (en) * 1997-12-29 2003-06-26 Novozymes A/S Modified enzymes
JP4424575B2 (en) * 1998-05-18 2010-03-03 ユニバーシティー カレッジ ロンドン Novel polypeptide hormone phosphatonin
US7022522B2 (en) 1998-11-13 2006-04-04 Limin Guan Macroporous polymer scaffold containing calcium phosphate particles
WO2001015720A1 (en) * 1999-09-02 2001-03-08 Big Bear Bio Inc. Methods and compositions for reducing serum phosphate levels
US6911425B2 (en) * 2000-08-16 2005-06-28 Acologix, Inc. Integrin binding motif containing peptides and methods of treating skeletal diseases
JP4638653B2 (en) * 2000-08-16 2011-02-23 アコロジックス インコーポレイテッド Dental products containing bone growth-promoting peptides
US6904123B2 (en) 2000-08-29 2005-06-07 Imaging Therapeutics, Inc. Methods and devices for quantitative analysis of x-ray images
AU2001286892B2 (en) 2000-08-29 2007-03-15 Imaging Therapeutics Inc. Methods and devices for quantitative analysis of x-ray images
US7467892B2 (en) * 2000-08-29 2008-12-23 Imaging Therapeutics, Inc. Calibration devices and methods of use thereof
US8639009B2 (en) 2000-10-11 2014-01-28 Imatx, Inc. Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
US7660453B2 (en) * 2000-10-11 2010-02-09 Imaging Therapeutics, Inc. Methods and devices for analysis of x-ray images
CA2445746C (en) * 2001-04-30 2012-09-18 City Of Hope Chimeric immunoreceptor useful in treating human cancers
ATE440536T1 (en) 2001-05-25 2009-09-15 Imaging Therapeutics Inc METHODS FOR DIAGNOSIS, TREATMENT AND PREVENTION OF BONE LOSS
US7491691B2 (en) * 2002-05-03 2009-02-17 Sindrey Dennis R Connective tissue stimulating peptides
US7840247B2 (en) * 2002-09-16 2010-11-23 Imatx, Inc. Methods of predicting musculoskeletal disease
US8965075B2 (en) * 2002-09-16 2015-02-24 Imatx, Inc. System and method for predicting future fractures
AU2003282867A1 (en) * 2002-10-22 2004-05-13 Genzyme Corporation Amine polymers for promoting bone formation
WO2004086972A2 (en) 2003-03-25 2004-10-14 Imaging Therapeutics, Inc. Methods for the compensation of imaging technique in the processing of radiographic images
US8290564B2 (en) 2003-09-19 2012-10-16 Imatx, Inc. Method for bone structure prognosis and simulated bone remodeling
EP1663002A4 (en) * 2003-09-19 2007-11-28 Imaging Therapeutics Inc Method for bone structure prognosis and simulated bone remodeling
EP1789924A2 (en) 2004-09-16 2007-05-30 Imaging Therapeutics, Inc. System and method of predicting future fractures
JP2008526871A (en) * 2005-01-07 2008-07-24 アコロジックス インコーポレイティッド Peptide formulations for periodontal and dental treatment
JP2009502782A (en) * 2005-07-18 2009-01-29 アコロジックス インコーポレイティッド Protein preparation for promoting hard tissue formation
WO2008034101A2 (en) * 2006-09-15 2008-03-20 Imaging Therapeutics, Inc. Method and system for providing fracture/no fracture classification
EP2117578B1 (en) * 2007-01-22 2015-04-22 OrthoTrophix, Inc. A peptide composition and a method of promoting cartilage formation
US8939917B2 (en) 2009-02-13 2015-01-27 Imatx, Inc. Methods and devices for quantitative analysis of bone and cartilage
TWI382852B (en) * 2009-12-22 2013-01-21 Univ Taipei Medical A calcium phosphate complex for oral care applications, its preparation method, and compositions containing the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007615A1 (en) * 1986-06-12 1987-12-17 The University Of Melbourne Phosphopeptides
GB2218317A (en) * 1988-05-12 1989-11-15 Itoh Feed Mills Co Ltd C Feed composition for fowls

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015A (en) * 1847-03-13 Mode of producing reciprocating and latkral motions
US5015628A (en) * 1986-06-12 1991-05-14 The University Of Melbourne Anticariogenic phosphopeptides
US5051401A (en) * 1989-04-07 1991-09-24 University Of South Alabama Inhibition of mineral deposition by phosphorylated and related polyanionic peptides
US5837674A (en) * 1996-07-03 1998-11-17 Big Bear Bio, Inc. Phosphopeptides and methods of treating bone diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007615A1 (en) * 1986-06-12 1987-12-17 The University Of Melbourne Phosphopeptides
GB2218317A (en) * 1988-05-12 1989-11-15 Itoh Feed Mills Co Ltd C Feed composition for fowls

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
AUST. J. CHEM. (1991), 44(2), 233-52, 1991 *
AUST. J. CHEM. (1991), 44(2), 253-63, 1991 *
AUST. J. CHEM. (1991), 44(3), 377-87, 1991 *
AUST. J. CHEM. (1991), 44(3), 389-96, 1991 *
AUST. J. CHEM. (1991), 44(3), 405-9, 1991 *
CEROVSKY, VACLAV ET AL: "Amino acids and peptides. Part CXCVIII. Enzymically catalyzed synthesis of dipeptides containing O4-sulfotyrosine and O4-phosphotyrosine", COLLECT. CZECH. CHEM. COMMUN. (1987), 52(4), 1079-86, 1987, XP002195833 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PERICH, JOHN W. ET AL: "Synthesis of casein-related peptides and phosphopeptides. IX. A modifie method for the synthesis of Ser(P) peptides by using Ppoc-Ser(PO3Bzl2)-OH", XP002195840, retrieved from STN Database accession no. 114:229369 CA *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PERICH, JOHN W. ET AL: "Synthesis of casein-related peptides and phosphopeptides. VII. The efficient synthesis of Ser(P)-Containing peptides by the use of Boc-Ser(PO3R2)-OH derivatives", XP002195842, retrieved from STN Database accession no. 114:186052 CA *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PERICH, JOHN W. ET AL: "Synthesis of casein-related peptides and phosphopeptides. VIII. The synthesis of Ser(P)-containing peptides by the use of Z-Ser(PO3R2)-OH derivatives", XP002195841, retrieved from STN Database accession no. 114:186053 CA *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PERICH, JOHN W. ET AL: "Synthesis of casein-related peptides and phosphopeptides. X. A modified method for the synthesis of Ser(P)-containing peptides through 4-bromobenzyl phosphate protection", XP002195839, retrieved from STN Database accession no. 114:229370 CA *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PERICH, JOHN W. ET AL: "Synthesis of casein-related peptides and phosphopeptides. XII. The synthesis of O-phosphoseryl-containing peptides with site-specific serine residues", XP002195843, retrieved from STN Database accession no. 114:229372 CA *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SCHLESINGER, DAVID H. ET AL: "Solution synthesis of phosphoseryl-phosphoserine, a partial analog of human salivary statherin essential for inhibition of primary and secondar precipitation of calcium phosphate", XP002195844, retrieved from STN Database accession no. 109:170837 CA *
G TONG ET AL.: "Synthesis of Leu-Abu(P) and Glu-Abu(P)-Leu. Isosteres of Ser(P) peptides", TETRAHEDRON LETTERS., vol. 31, no. 26, 1990, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM., NL, pages 3759 - 3762, XP002196435, ISSN: 0040-4039 *
HIPP, N. J. ET AL: "Phosphopeptides obtained by partial acid hydrolysis of.alpha.-casein", J. AM. CHEM. SOC. (1957), 79, 2559-65, 1957, XP002195834 *
KITAS, ERIC A. ET AL: "Synthesis of O-phosphotyrosine-containing peptides. 3. Synthesis of H-Pro-Tyr(P)-Val-OH via dimethyl phosphate protection and the use of improved deprotection procedures", J. ORG. CHEM. (1990), 55(13), 4181-7, 1990, XP002195837 *
PEPT. CHEM. (1988), VOLUME DATE 1987 311-14, 1988 *
PERICH, J. W. ET AL: "Solution-phase synthesis of an O-phosphoseryl-containing peptide using phenyl phosphorotriester protection", TETRAHEDRON LETT. (1986), 27(12), 1373-6, 1986, XP002195838 *
POSTERNAK, THEODORE ET AL: "Casein phosphopeptones (lactotyrines)", HELV. CHIM. ACTA (1941), 24, 1190-1210, 1941, XP002195835 *
UENO, YOSHIHITO ET AL: "Chemical synthesis of phosphopeptides using the arylthio groups for protection of phosphate: application to identification of cdc2 kinase phosphorylation sites", INT. J. PEPT. PROTEIN RES. (1995), 46(2), 106-12, 1995, XP000520071 *

Also Published As

Publication number Publication date
DK0938326T3 (en) 2005-01-03
DE69730725T2 (en) 2006-02-23
PT938326E (en) 2004-11-30
ATE275961T1 (en) 2004-10-15
US6306822B1 (en) 2001-10-23
AU727675B2 (en) 2000-12-21
AU3587197A (en) 1998-01-21
DE69730725D1 (en) 2004-10-21
ES2224260T3 (en) 2005-03-01
EP0938326B1 (en) 2004-09-15
CA2258661A1 (en) 1998-01-08
JP2004067687A (en) 2004-03-04
WO1998000156A1 (en) 1998-01-08
US5837674A (en) 1998-11-17
EP0938326A1 (en) 1999-09-01
CA2258661C (en) 2002-09-10
JP2001503452A (en) 2001-03-13

Similar Documents

Publication Publication Date Title
EP0938326A4 (en) Synthetic phosphopeptides for treating bone diseases
ATE185971T1 (en) COMBINATION PREPARATION FOR THE TREATMENT OF HYPOGONADAL MEN AND MEN WITH HYPOPHYSIS DISEASES
BG102999A (en) New 2,3-diasubstituted-4-(3h)-quinazolinons
ZA971937B (en) Combinations for treatment of proliferative diseases.
ZA941890B (en) Method for making soft tissue.
EP0895781A3 (en) Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins
ZA964886B (en) Suture guard for prosthetic heart valve.
ZA963694B (en) Methods for inhibiting bone loss.
DE69415231D1 (en) Interlocking, multi-part endossal dental implant
EP0625340A3 (en) Sleeve for healing promotion of bone defects.
EP0648477A3 (en) Drill head for the medullary canal.
ES2170174T3 (en) CONTINUOUS PROCESS FOR THE PREPARATION OF POLYAMIDS.
PH31315A (en) Methods for inhibiting bone loss using substitutedbenzothiophene.
ZA977948B (en) Process for the control of weeds.
AU3236695A (en) Syringe system for matching tooth composite colors
EP1632248B8 (en) Anti-interleukin-9 antibody or anti-interleukin-9 receptor antibody for treating bronchial hyper-responsiveness
AU2825295A (en) Method for the treatment, prevention or minimization of hair loss
ES2196539T3 (en) FACILITATION OF CICATRIZATION WITH THE TOXIN CM101 / GBS.
AU7654298A (en) A method for the improvement of neuronal regeneration
EP0621013A3 (en) Periodontal tissue regrowth guiding implant.
EP1039883A4 (en) Methods for the treatment of apolipoprotein e related diseases
DE59709891D1 (en) Liner, especially for ski boots, mountain boots or the like
MXPA02002315A (en) Methods and compositions for reducing serum phosphate levels.
ZA978640B (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis.
EP0672457A3 (en) Method for the residue-free waste treatment.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/00 A, 7A 61K 38/04 B, 7A 61K 38/16 B, 7C 07K 5/00 B, 7C 07K 7/00 B, 7C 07K 17/00 B, 7C 07K 14/00 B, 7C 07K 7/06 B, 7C 07K 7/08 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020521

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

17Q First examination report despatched

Effective date: 20021014

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69730725

Country of ref document: DE

Date of ref document: 20041021

Kind code of ref document: P

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20040403423

Country of ref document: GR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20041012

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2224260

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20050616

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20070603

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20070607

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20070614

Year of fee payment: 11

Ref country code: AT

Payment date: 20070614

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20070615

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20070618

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20070625

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20070627

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20070628

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20070717

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20070627

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20070612

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20070822

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20070608

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20070514

Year of fee payment: 11

BERE Be: lapsed

Owner name: *ACOLOGIX INC.

Effective date: 20080630

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20081231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081231

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20080630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080630

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20090101

EUG Se: european patent has lapsed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080630

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20090228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080630

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090101

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080630

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090107

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080630

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20080701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080630

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080701